Delcath Sys Stock Price, News & Analysis

Delcath Systems Inc (Nasdaq: DCTH) is an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver. Operating in the surgical and medical instrument manufacturing industry within the broader manufacturing sector, Delcath develops and commercializes proprietary drug–device technologies designed to deliver high-dose chemotherapy directly to the liver while limiting systemic exposure and related side effects.

The company’s business centers on its hepatic delivery technologies, which are used in a procedure known as percutaneous hepatic perfusion (PHP). According to company disclosures, Delcath operates through a single reportable segment that encompasses the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific liver-related conditions. The company conducts business in the United States and Europe.

Core products and technology

Delcath’s proprietary products are HEPZATO KIT™ and the CHEMOSAT® Hepatic Delivery System (HDS) for Melphalan. Both are designed to administer high-dose melphalan chemotherapy to the liver during a PHP procedure while controlling systemic exposure.

• HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System): In the United States, HEPZATO KIT is treated as a combination drug and device product and is regulated and approved for sale as a drug by the U.S. Food and Drug Administration (FDA. The kit combines the chemotherapeutic drug melphalan with Delcath’s proprietary Hepatic Delivery System (HDS).
• CHEMOSAT Hepatic Delivery System (HDS) for Melphalan: In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT. It has been used at major medical centers in percutaneous hepatic perfusion procedures to treat a range of cancers of the liver.

The HDS component is used to isolate hepatic venous blood from the systemic circulation while simultaneously filtrating the hepatic venous blood during melphalan infusion and washout. Company materials state that this approach results in loco-regional delivery of a relatively high melphalan dose that can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduced systemic exposure.

Therapeutic focus and indications

Delcath’s primary therapeutic focus is on metastatic uveal melanoma (mUM) and other cancers involving the liver. The company describes itself as focused on the treatment of primary and metastatic liver cancers, with a particular emphasis on liver-dominant metastatic disease.

In the United States, HEPZATO KIT is approved as a liver-directed treatment for adult patients with metastatic uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. The company notes that full prescribing information, including a boxed warning, applies to the product.

In Europe, CHEMOSAT has been used in PHP procedures at major medical centers to treat a wide range of cancers of the liver. Published data cited in company news releases describe use of CHEMOSAT in liver-dominant metastatic uveal melanoma and other liver metastases, with studies examining survival outcomes, disease control, and the role of repeated PHP cycles.

Clinical evidence and research activity

Delcath’s technologies are supported by a body of clinical and real-world evidence referenced in its public communications. The company highlights:

• A Phase 3 FOCUS study of Melphalan/Hepatic Delivery System in patients with unresectable metastatic uveal melanoma, which led to the FDA approval of HEPZATO. Subgroup analyses of this study have been published, assessing efficacy and safety across factors such as age, sex, geographic region, tumor burden, extent of liver involvement, extrahepatic lesions, baseline LDH, and prior therapies.
• The CHOPIN Phase 2 trial, sponsored by Leiden University Medical Center, evaluating CHEMOSAT with the immune checkpoint inhibitors ipilimumab and nivolumab in metastatic uveal melanoma. Company disclosures report a significant improvement in one-year progression-free survival for the combination versus CHEMOSAT alone.
• A 10-year single-center experience from Asklepios Hospital Barmbek in Hamburg, Germany, using CHEMOSAT for liver-dominant metastatic uveal melanoma, reporting safety and efficacy outcomes over multiple PHP procedures.
• A retrospective analysis from the University of Tübingen examining long-term survivors with liver metastases from uveal melanoma, which underscores the potential benefits of early use of liver-directed therapies, including PHP, in achieving long-term survival.
• An expert narrative review in the Journal of Vascular and Interventional Radiology summarizing the rationale, technique, patient selection, clinical outcomes, and research directions for PHP with melphalan using HEPZATO KIT, and emphasizing its role as an FDA-approved liver-directed therapy for unresectable hepatic metastases from uveal melanoma with limited extrahepatic disease.

These publications and analyses, as described in Delcath’s news releases, collectively present data on objective response rates, progression-free survival, overall survival, disease control rates, safety profiles, and the impact of tumor burden and treatment sequencing on outcomes in metastatic uveal melanoma and liver-dominant disease.

Geographic footprint and regulatory status

Delcath reports that it operates its business in the United States and Europe. In the U.S., HEPZATO KIT is FDA-approved and regulated as a drug–device combination product. In Europe, the CHEMOSAT Hepatic Delivery System is regulated as a Class III medical device and approved for sale under the CHEMOSAT trade name.

The company’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Capital Market under the symbol DCTH, as confirmed in multiple Form 8-K filings. These filings also show that Delcath is incorporated in Delaware and files periodic and current reports with the U.S. Securities and Exchange Commission (SEC).

Corporate and financial reporting

Delcath communicates its financial and operational performance through press releases and SEC filings, including Form 8-K reports on quarterly results, preliminary financial updates, and other material events. Recent disclosures describe product revenue derived from HEPZATO KIT in the United States and CHEMOSAT in Europe, as well as information on gross margins, operating expenses, and cash and investment balances. The company also reports on non-GAAP measures such as adjusted EBITDA and explains the rationale for presenting these metrics alongside GAAP results.

In addition, Delcath has disclosed the authorization of a share repurchase program under which the board of directors approved the repurchase of up to a specified dollar amount of outstanding common stock, subject to market conditions. The company has also reported equity inducement grants under a stock incentive plan, consistent with Nasdaq listing rules.

Governance and regulatory disclosures

Delcath’s SEC filings indicate ongoing corporate governance activity, including amendments and restatements of its bylaws. An 8-K filing describes updates to advance notice provisions for stockholder nominations and proposals, officer and chairperson election provisions, indemnification rights for directors, officers and other agents, and various administrative and clarifying changes.

The company’s filings also include standard forward-looking statement disclosures under the Private Securities Litigation Reform Act of 1995, noting that certain statements about financial outlook, clinical development, and business plans are subject to risks and uncertainties.

Position within the medical device and oncology landscape

Within the broader manufacturing sector, Delcath is classified in surgical and medical instrument manufacturing, with a specialized focus on interventional oncology and liver-directed therapies. Its business model centers on proprietary hepatic delivery systems and associated drug–device combinations used in PHP procedures for patients with liver metastases, particularly metastatic uveal melanoma.

By concentrating on loco-regional chemotherapy delivery to the liver and supporting this approach with clinical trials, retrospective analyses, and expert reviews, Delcath positions its technologies as options for managing liver-dominant metastatic disease in settings where systemic exposure to chemotherapy must be controlled. The company’s disclosures emphasize the potential for high-dose melphalan delivery with controlled systemic exposure, the role of PHP in multimodal treatment strategies, and the use of its products at specialized centers in the U.S. and Europe.

FAQs about Delcath Systems Inc (DCTH)

• What does Delcath Systems Inc do?
  Delcath Systems Inc is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. It develops, manufactures, and distributes hepatic delivery systems designed to administer high-dose melphalan chemotherapy to the liver while limiting systemic exposure during percutaneous hepatic perfusion procedures.
• What are Delcath’s main products?
  Delcath’s main proprietary products are HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) in the United States and the CHEMOSAT Hepatic Delivery System for Melphalan in Europe. Both are used to deliver high-dose melphalan to the liver in a controlled manner during PHP procedures.
• For which indication is HEPZATO KIT approved in the United States?
  HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
• How is CHEMOSAT regulated in Europe?
  In Europe, the device-only configuration of Delcath’s Hepatic Delivery System is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. It has been used at major medical centers in percutaneous hepatic perfusion procedures to treat a range of cancers of the liver.
• What is percutaneous hepatic perfusion (PHP) in Delcath’s context?
  In Delcath’s context, PHP is a procedure in which high-dose melphalan is delivered directly to the liver while hepatic venous blood is isolated from the systemic circulation and filtered using the company’s Hepatic Delivery System. This approach is intended to achieve loco-regional chemotherapy delivery with reduced systemic exposure and associated side effects.
• What clinical data support Delcath’s technologies?
  Company communications reference several sources of clinical and real-world evidence, including the Phase 3 FOCUS study of Melphalan/Hepatic Delivery System in unresectable metastatic uveal melanoma, the Phase 2 CHOPIN trial evaluating CHEMOSAT with ipilimumab and nivolumab, a 10-year single-center experience with CHEMOSAT in liver-dominant metastatic uveal melanoma, retrospective analyses of long-term survivors with liver metastases from uveal melanoma, and an expert narrative review of PHP using HEPZATO KIT.
• Where does Delcath operate?
  Delcath reports that it operates its business in the United States and Europe. HEPZATO KIT is approved and marketed in the U.S., while CHEMOSAT is approved as a Class III medical device in Europe and used at major medical centers for liver-directed therapies.
• On which exchange is Delcath Systems Inc listed and what is its ticker?
  Delcath Systems Inc’s common stock is listed on The Nasdaq Capital Market under the ticker symbol DCTH, as disclosed in its SEC filings.
• How does Delcath describe its business segment structure?
  According to company descriptions, Delcath operates in one reportable segment that includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions involving the liver.
• What types of corporate events does Delcath report in SEC filings?
  Delcath uses SEC filings, including Form 8-K, to report events such as quarterly and preliminary financial results, authorization of share repurchase programs, amendments to bylaws, and updates on clinical trial outcomes and revenue guidance, along with standard forward-looking statement and non-GAAP measure disclosures.